Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.59 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | TSPO | P30536 | 1/20 | 0.57 |
| ▸ | BRD2 | P25440 | 5/20 | 0.57 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12186087 | 0.91 | BRD4 (0.59) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL881272 | 0.91 | BRD4 (0.70) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL12152375 | 0.91 | BRD4 (0.70) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL15114804 | 0.85 | BRD4 (0.71) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL18199864 | 0.85 | BRD4 (0.71) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL24490767 | 0.83 | BRD4 (0.76) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL881277 | 0.83 | BRD4 (0.76) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL12186083 | 0.83 | BRD4 (0.63) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL21142331 | 0.83 | BRD4 (0.61) | BRD4BRDTADORA3TSPOBRD2 | |
| SCHEMBL23321129 | 0.81 | BRD4 (0.79) | BRD4BRDTADORA3TSPOBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | BRD4 205/4885BRDT 85/4885ADORA3 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.